NCT04530136: A trial that was reported late by Pharming Technologies B.V.
This trial has reported, although it was 168 days late in doing so.
|Full entry on ClinicalTrials.gov||NCT04530136|
|Title||Recombinant Human C1 Esterase Inhibitor (Ruconest®) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the United States (PROTECT-COVID-19-US)|
|Results Status||Reported (late)|
|ACT or pACT?||This is what FDAAA officially calls an "Applicable Clinical Trial"|
|Start date||Nov. 30, 2020|
|Completion date||Sept. 7, 2021|
|Required reporting date||Sept. 7, 2022, midnight|
|Actual reporting date||Feb. 22, 2023|
|Date last checked at ClinicalTrials.gov||April 10, 2023|